Lupus Nephritis Clinical Trials

72 recruitingLast updated: June 18, 2026

There are 72 actively recruiting lupus nephritis clinical trials across 47 countries. Studies span Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1, Not Applicable. Top locations include New York, New York, United States, Atlanta, Georgia, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Lupus Nephritis Trials at a Glance

72 actively recruiting trials for lupus nephritis are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Phase 2 with 26 trials, with the heaviest enrollment activity in New York, Atlanta, and Houston. Lead sponsors running lupus nephritis studies include Novartis Pharmaceuticals, China Immunotech (Beijing) Biotechnology Co., Ltd., and Sohag University.

Browse lupus nephritis trials by phase

Treatments under study

About Lupus Nephritis Clinical Trials

Looking for clinical trials for Lupus Nephritis? There are currently 49 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lupus Nephritis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lupus Nephritis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 72 trials

Recruiting
Phase 1

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

Lupus Nephritis (LN)
Regeneron Pharmaceuticals90 enrolled17 locationsNCT06975787
Recruiting
Phase 1Phase 2

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

CAR-T CellSLESystemic Lupus Erythematosus (SLE)+4 more
Children's Hospital of Philadelphia24 enrolled1 locationNCT06839976
Recruiting
Phase 4

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

Lupus Nephritis
Aurinia Pharmaceuticals Inc.150 enrolled15 locationsNCT07611214
Recruiting
Phase 1

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

SLE (Systemic Lupus)Diffuse Cutaneous Systemic SclerosisSystemic Sclerosis+4 more
CRISPR Therapeutics80 enrolled14 locationsNCT06925542
Recruiting
Phase 1

NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis

Refractory Lupus NephritisRefractory Systemic Lupus Erythematosus
Guangdong Provincial People's Hospital18 enrolled1 locationNCT06676631
Recruiting
Phase 1

US Zamto-cel Autoimmune Diseases

Systemic Lupus ErythematosusDiffuse Cutaneous Systemic SclerosisSystemic Sclerosis (SSc)+1 more
Miltenyi Biomedicine GmbH48 enrolled1 locationNCT06708845
Recruiting
Phase 2

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

Lupus Erythematosus, SystemicLupus Nephritis
Novartis Pharmaceuticals179 enrolled101 locationsNCT06581198
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Lupus NephritisPrimary Membranous Nephropathy
Nkarta, Inc.120 enrolled19 locationsNCT06557265
Recruiting
Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Lupus Nephritis
Hoffmann-La Roche40 enrolled42 locationsNCT05039619
Recruiting
Phase 2

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Lupus Erythematosus, SystemicLupus Nephritis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company89 enrolled95 locationsNCT07015983
Recruiting
Phase 2

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Lupus Nephritis
Novartis Pharmaceuticals240 enrolled103 locationsNCT05268289
Recruiting
Phase 2

A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Systemic Lupus ErythematosusLupusLupus Nephritis
Hoffmann-La Roche30 enrolled15 locationsNCT07598396
Recruiting
Phase 4

Dapagliflozin in Active Lupus Nephritis

Lupus Nephritis (LN)
Brigham and Women's Hospital33 enrolled2 locationsNCT07323524
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled21 locationsNCT06308978
Recruiting
Phase 2

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis

Lupus Nephritis
Autolus Limited35 enrolled26 locationsNCT07053800
Recruiting
Phase 1Phase 2

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Systemic Lupus ErythematosusLupusAutoimmune Disorders+2 more
M.D. Anderson Cancer Center47 enrolled2 locationsNCT06434363
Recruiting

Lupus Landmark Study: A Prospective Registry and Biorepository

Systemic Lupus Erythematosus (SLE)Lupus NephritisNeuropsychiatric Systemic Lupus Erythematosus
Lupus Research Alliance3,500 enrolled25 locationsNCT05934149
Recruiting
Phase 1Phase 2

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Systemic Lupus ErythematosusLupus Nephritis
Cabaletta Bio28 enrolled23 locationsNCT06121297
Recruiting
Phase 1Phase 2

SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus

Lupus NephritisRefractory Systemic Lupus Erythematosus
Beijing Biotech24 enrolled1 locationNCT07523542
Recruiting

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

Lupus Nephritis
GlaxoSmithKline300 enrolled5 locationsNCT06527872